Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

A novel bifunctional fusion protein for combatting lung cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.10.18
Views: 434

Dr Luis Paz-Ares - Hospital Universitario, Madrid, Spain

Dr Luis Paz-Ares speaks to ecancer at ESMO 2018 in Munich about a clinical trial that uses a novel bifunctional fusion protein (M7824).

The findings include a high rate of response in patients whose tumours expressed high levels of PDL1, and links that to improved PFS in some patients.

Dr Paz-Ares concludes by describing exploratory avenues to expand research with the molecule.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Core Surgical Training

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation